Cytomorphology
Flow cytometry
Molecular aberrations (cytogenetic, genetic, gene expression)

Cost of care
Patient-reported outcomes
Efficacy outcome measures

Normal, MDS, and leukemic stem cells
Clonal diversity & evolution
MDS Mouse models (GEMMS, PDX)
Somatic mutations
Spliceosome machinery
Gene expression profiling
Epigenetic deregulation
Immune deregulation / inflammation
Microenvironment and stem cell niche

Prognostic factors of outcome and risk assessment
Predictive factors of response to treatment

Subtypes-ARCH, CCUS, ICUS
MDS in childhood
Hereditary MDS including predisposition syndromes
MDS with ring sideroblasts
Chronic myelomonocytic leukemia and overlap syndromes (MDS – MPN)
MDS with deletion 5q
Treatment-related MDS

Current treatment options – Higher risk MDS
Current treatment options – Lower risk MDS
Current treatment options -Immunosuppressive therapy
New developments – Preclinical studies
New developments – Phase I studies
Clinical trials – Phase II-III
Allogeneic hematopoietic cell transplantation -Bridging to transplantation
Allogeneic hematopoietic cell transplantation -Post-transplantation treatment
observational studies
Supportive care, transfusion medicine and MDS, iron overload
Supportive care, Geriatric issues and MDS

Disease experiences